Fortress Biotech, Inc. (FBIOP) Return on equity 2016–2025
Fortress Biotech, Inc. (FBIOP) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
13.7%FY2025 · since FY2016: -143.1% → 13.7%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 13.7% | +216.0 pp |
| FY2024 | -202.3% | +66.7 pp |
| FY2023 | -269.0% | -61.5 pp |
| FY2022 | -207.5% | -148.0 pp |
| FY2021 | -59.5% | -13.2 pp |
| FY2020 | -46.4% | +106.1 pp |
| FY2019 | -152.4% | +4391.1 pp |
| FY2018 | -4543.6% | -4416.4 pp |
| FY2017 | -127.2% | +15.9 pp |
| FY2016 | -143.1% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More FBIOP financial trends
FBIOP RevenueFBIOP Net incomeFBIOP Net marginFBIOP Gross profitFBIOP Gross marginFBIOP Operating incomeFBIOP Operating marginFBIOP Operating cash flowFBIOP Free cash flowFBIOP Capital expendituresFBIOP Stock buybacksFBIOP Dividends paidFBIOP Total assetsFBIOP Total liabilitiesFBIOP Shareholders’ equityFBIOP overview →